Ultomiris IgA Nephropathy
AstraZeneca’s ULTOMIRIS: THE FIRST C5 INHIBITOR ENTERS THE RACE TO TAME PROTEINURIA IN IgA NEPHROPATHY
KIDNEY DISEASE TREATMENT IS ENTERING A NEW CHAPTER AS COMPLEMENT-TARGETED MEDICINES GAIN ATTENTION THROUGH AI IN HEALTHCARE INNOVATIONS. ON OCTOBER 21, 2026, THE US FOOD AND DRUG ADMINISTRATION (FDA) GRANTED ACCELERATED APPROVAL TO ULTOMIRIS (RAVULIZUMAB-CWVZ) TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IgA NEPHROPATHY (IgAN) AT RISK OF DISEASE PROGRESSION. DEVELOPED BY ASTRAZENECA THROUGH ALEXION, THE MONOCLONAL ANTIBODY MEDICINE INTRODUCES TERMINAL C5 INHIBITION INTO AN INCREASINGLY COMPETITIVE IgAN TREATMENT LANDSCAPE.
THE DECISION FOLLOWS PROMISING FINDINGS FROM THE I CAN PHASE III CLINICAL TRIAL, WHICH DEMONSTRATED A 43.4% PLACEBO-ADJUSTED REDUCTION IN PROTEINURIA FROM BASELINE AT WEEK 34 (MEASURED VIA 24-HOUR URINE PROTEIN-TO-CREATININE RATIO or UPCR). HOWEVER, ONE IMPORTANT QUESTION REMAINS FOR CLINICIANS MONITORING LAB RESULT EXPLAINER GUIDE METRICS: CAN ULTOMIRIS FOR IgA NEPHROPATHY PROTECT KIDNEY FUNCTION PRESERVATION AND PREVENT END-STAGE KIDNEY DISEASE (ESKD) OVER THE LONG-TERM CLINICAL BENEFIT HORIZON? THE ONGOING TRIAL WILL HELP ANSWER THIS QUESTION THROUGH ITS WEEK 106 eGFR ENDPOINT ASSESSMENT.
IgA NEPHROPATHY: A QUIET DISEASE WITH A HEAVY BURDEN
IgA NEPHROPATHY, ALSO CALLED BERGER’S DISEASE, IS AN IMMUNE-MEDIATED KIDNEY CONDITION THAT DEVELOPS WHEN ABNORMAL ANTIBODIES ACCUMULATE INSIDE THE GLOMERULI. ALONG WITH ADVANCES IN AI-BASED DIABETES MANAGEMENT, modern nephrology tracks these cascades closely. THE DISEASE OFTEN BEGINS WITH GALACTOSE-DEFICIENT IgA1, WHICH COMBINES WITH OTHER ANTIBODIES TO FORM IgA IMMUNE COMPLEXES. THESE DEPOSITS ACTIVATE THE COMPLEMENT CASCADE, TRIGGERING GLOMERULAR INFLAMMATION AND DAMAGING THE KIDNEY FILTRATION BARRIER. CONSEQUENTLY, BLOOD AND PROTEIN CAN LEAK INTO URINE.
WHAT MAKES IgAN PARTICULARLY CONCERNING IS ITS UNPREDICTABLE PROGRESSION. SOME PATIENTS EXPERIENCE HEMATURIA OR PERSISTENT PROTEINURIA, WHILE OTHERS DISCOVER ABNORMALITIES DURING ROUTINE URINALYSIS OR VIA A LAB RESULT EXPLAINER GUIDE assessment. A KIDNEY BIOPSY USUALLY CONFIRMS THE DIAGNOSIS. OVER TIME, UNCONTROLLED DISEASE CAN CAUSE CHRONIC KIDNEY DISEASE (CKD) AND EVENTUALLY END-STAGE KIDNEY DISEASE (ESKD). PERSISTENT PROTEIN LEAKAGE THEREFORE DESERVES ATTENTION BECAUSE IT SIGNALS ONGOING KIDNEY INJURY AND INCREASED DISEASE PROGRESSION RISK.
PATHOPHYSIOLOGY & BIOMARKERS
CHARACTERIZED BY GALACTOSE-DEFICIENT IgA1 DEPOSITS, COMPLEMENT ACTIVATION, AND SUBSEQUENT DAMAGE TO THE KIDNEY FILTRATION BARRIER LEADING TO PROTEINURIA.
DIAGNOSIS & MONITORING TOOLS
IDENTIFIED THROUGH URINALYSIS, CONFIRMED VIA KIDNEY BIOPSY, AND EVALUATED ALONGSIDE TOOLS LIKE THE EGFR CALCULATOR TO TRACK CHRONIC KIDNEY DISEASE (CKD) TRAJECTORIES.
ULTOMIRIS MoA: WHY BLOCKING C5 MAKES SENSE IN IgAN
THE SCIENCE BEHIND ULTOMIRIS FOR IgA NEPHROPATHY CENTERS ON RAVULIZUMAB-CWVZ, A LONG-ACTING COMPLEMENT INHIBITION MONOCLONAL ANTIBODY THAT TARGETS COMPLEMENT COMPONENT C5. IT PREVENTS C5 CLEAVAGE INTO COMPLEMENT COMPONENT C5a AND COMPLEMENT COMPONENT C5b, SUPPRESSING THE TERMINAL COMPLEMENT PATHWAY AND FORMATION OF THE MEMBRANE ATTACK COMPLEX (C5b-9). THIS APPROACH AIMS TO REDUCE COMPLEMENT-MEDIATED KIDNEY INJURY WITHOUT DIRECTLY REMOVING THE ORIGINAL IgA IMMUNE COMPLEXES. ADHERING TO CLINICAL PROTOCOLS SIMILAR TO RULES FOR HEALTHCARE AI GOVERNANCE, BIOMARKER TARGETING ENSURES PRECISE THERAPEUTIC DELIVERY.
IgAN INVOLVES SEVERAL COMPLEMENT MECHANISMS. THE CLASSICAL COMPLEMENT PATHWAY, LECTIN COMPLEMENT PATHWAY, AND ALTERNATIVE COMPLEMENT PATHWAY EVENTUALLY CONVERGE ON TERMINAL COMPLEMENT ACTIVATION. IN PARTICULAR, ALTERNATIVE AND LECTIN PATHWAY ACTIVITY HAS BEEN IMPLICATED IN PRIMARY IgA NEPHROPATHY (IgAN). BY BLOCKING C5 DOWNSTREAM OF THESE ACTIVATION ROUTES, RAVULIZUMAB MAY INTERRUPT INFLAMMATORY SIGNALS AND CELLULAR INJURY IN GLOMERULI. HOWEVER, THE TREATMENT DOES NOT CORRECT THE UNDERLYING PRODUCTION OF GALACTOSE-DEFICIENT IgA1 ABNORMAL ANTIBODIES.
THE CLINICAL EVIDENCE BEGAN WITH THE SANCTUARY PHASE II TRIAL, WHERE RAVULIZUMAB REDUCED 24-HOUR URINARY PROTEIN BY 41.9% AT WEEK 26 COMPARED WITH 16.8% FOR PLACEBO. ITS SUBSEQUENT PHASE III EVALUATION STRENGTHENED THE EVIDENCE. IN THE I CAN PHASE III CLINICAL TRIAL, RESEARCHERS RANDOMIZED 485 ADULTS TO RECEIVE RAVULIZUMAB OR PLACEBO. THE PRESPECIFIED WEEK 34 INTERIM ANALYSIS INCLUDED 352 PARTICIPANTS AND ASSESSED THE 24-HOUR URINE PROTEIN-TO-CREATININE RATIO (UPCR) AT WEEK 34.
| CLINICAL MEASUREMENT | ULTOMIRIS | PLACEBO |
|---|---|---|
| REDUCTION AT WEEK 10 (WEEK 10 TREATMENT RESPONSE) | 36.7% | 8.5% |
| REDUCTION AT WEEK 34 (WEEK 34 INTERIM ANALYSIS) | 46.6% | 5.6% |
| PLACEBO-ADJUSTED REDUCTION AT WEEK 34 | 43.4% | — |
THE WEEK 10 TREATMENT RESPONSE SUGGESTS AN EARLY EFFECT, WHILE THE WEEK 34 RESULTS DEMONSTRATE SUSTAINED PROTEINURIA REDUCTION DURING THE REPORTED PERIOD. NEVERTHELESS, THE WEEK 106 eGFR ENDPOINT REMAINS ESSENTIAL FOR DETERMINING WHETHER TREATMENT SLOWS KIDNEY FUNCTION DECLINE AND PRESERVES THE ESTIMATED GLOMERULAR FILTRATION RATE (eGFR). COMPARING DIAGNOSTIC LOGS VIA A LAB RESULT EXPLAINER GUIDE OFFERS CLINICAL INSIGHTS DURING ACCELERATED PHASE ASSESSMENTS. THE TRIAL’S RESULTS SUPPORT THE FDA ACCELERATED APPROVAL VIA A SURROGATE CLINICAL ENDPOINT, BUT THEY DO NOT YET ESTABLISH LONG-TERM CLINICAL BENEFIT.
SAFETY ALSO DESERVES ATTENTION FOR ONCOLOGISTS AND NEPHROLOGISTS UTILIZING AI TOOLS FOR ONCOLOGISTS AND CLINICAL DECISION SUPPORT SYSTEMS. ULTOMIRIS CARRIES A BOXED WARNING FOR SERIOUS MENINGOCOCCAL INFECTION, WHICH CAN BECOME LIFE-THREATENING UNDER COMPLEMENT SUPPRESSION.
PATIENTS REQUIRE APPROPRIATE MENINGOCOCCAL VACCINATION PRIOR TO INITIATING INTRAVENOUS INFUSION TREATMENT, ALONGSIDE STAGE-SPECIFIC INFECTION MONITORING AND ADHERENCE TO THE MANDATED RISK EVALUATION AND MITIGATION STRATEGY (REMS) PROGRAM. IN THE I CAN TRIAL INTERIM ANALYSIS, COMMON ADVERSE EVENTS INCLUDED UPPER RESPIRATORY INFECTIONS, NASOPHARYNGITIS, AND INFUSION-RELATED REACTIONS.
THE NEW LANDSCAPE OF IgA NEPHROPATHY TREATMENTS
THE IgAN TREATMENT LANDSCAPE HAS CHANGED CONSIDERABLY, MOVING BEYOND BLOOD PRESSURE CONTROL AND CONVENTIONAL SUPPORTIVE CARE. THE KDIGO 2025 GUIDELINE EMPHASIZES KIDNEY PROTECTION THROUGH LIFESTYLE MEASURES, RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS. TARGETED THERAPIES ALSO ADDRESS DIFFERENT STAGES OF DISEASE BIOLOGY. THESE APPROACHES AIM TO REDUCE PROTEINURIA WHILE PRESERVING THE ESTIMATED GLOMERULAR FILTRATION RATE (eGFR).
SEVERAL MEDICINES NOW OFFER DISTINCT TREATMENT APPROACHES:
-
TARPEYO (BUDESONIDE)
DELIVERS TARGETED-RELEASE CORTICOSTEROID THERAPY.
-
FILSPARI (SPARSENTAN)
BLOCKS ENDOTHELIN AND ANGIOTENSIN II RECEPTORS.
-
VANRAFIA (ATRASENTAN)
TARGETS THE ENDOTHELIN A RECEPTOR.
-
TRUTAKNA (ATACICEPT)
ACTS ON B-CELL-RELATED IMMUNE PATHWAYS.
-
VOYXACT (SIBEPRENLIMAB)
TARGETS THE APRIL PATHWAY.
-
ULTOMIRIS
INTRODUCES TERMINAL COMPLEMENT INHIBITION INTO THIS EXPANDING TREATMENT CATEGORY.
THESE MEDICINES SHOULD NOT BE TREATED AS INTERCHANGEABLE OPTIONS. THEIR MECHANISMS, CLINICAL ENDPOINTS, ADMINISTRATION SCHEDULES AND SAFETY PROFILES DIFFER. FOR EXAMPLE, SOME TREATMENTS TARGET ABNORMAL ANTIBODY PRODUCTION, WHILE OTHERS REDUCE INFLAMMATORY INJURY OR PROTECT KIDNEY FILTRATION. THE GROWING RANGE OF IgA NEPHROPATHY TREATMENT OPTIONS MAKES INDIVIDUALIZED ASSESSMENT INCREASINGLY IMPORTANT, PARTICULARLY FOR PATIENTS WHO CONTINUE EXPERIENCING PROTEINURIA DESPITE STANDARD CARE.
ULTOMIRIS APPROVAL TIMELINE IN THE US
VISUAL MILESTONE ROADMAP OF RAVULIZUMAB-CWVZ FROM LAUNCH TO IgA NEPHROPATHY ACCELERATED APPROVAL.
C5 vs. FACTOR B: TWO COMPLEMENT STRATEGIES, TWO DIFFERENT TARGETS
ALTHOUGH BOTH MEDICINES BELONG TO THE COMPLEMENT-INHIBITION CATEGORY, ULTOMIRIS AND FABHALTA INTERVENE AT DIFFERENT POINTS. ULTOMIRIS BLOCKS C5 NEAR THE END OF THE COMPLEMENT CASCADE, WHILE FABHALTA (IPTACOPAN) ACTS EARLIER THROUGH FACTOR B INHIBITION WITHIN THE ALTERNATIVE COMPLEMENT PATHWAY. FACTOR B CONTRIBUTES TO C3 CONVERTASE AND C5 CONVERTASE ACTIVITY, MAKING IT AN IMPORTANT PART OF COMPLEMENT AMPLIFICATION. REINFORCING CLINICAL WORKFLOWS WITH AI-BASED DIABETES MANAGEMENT PLATFORMS HELPS OPTIMIZE MULTI-CONDITION MONITORING.
| FEATURE | ULTOMIRIS | FABHALTA |
|---|---|---|
| ACTIVE INGREDIENT | RAVULIZUMAB | IPTACOPAN |
| TARGET | COMPLEMENT COMPONENT C5 | FACTOR B |
| MECHANISM | TERMINAL COMPLEMENT INHIBITION | ALTERNATIVE PATHWAY INHIBITION |
| ADMINISTRATION | INTRAVENOUS INFUSION | ORAL CAPSULE |
| MAINTENANCE SCHEDULE | EVERY 8 WEEKS | TWICE DAILY |
| FDA IgAN STATUS | ACCELERATED APPROVAL | TRADITIONAL APPROVAL |
AN IMPORTANT REGULATORY DEVELOPMENT OCCURRED ON JULY 17, 2026, WHEN NOVARTIS ANNOUNCED TRADITIONAL FDA APPROVAL FOR FABHALTA TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS WITH PRIMARY IgA NEPHROPATHY (IgAN). ITS PHASE III EVIDENCE DEMONSTRATED A 48% REDUCTION IN eGFR DECLINE COMPARED WITH PLACEBO OVER TWO YEARS, ACCORDING TO THE MANUFACTURER. TRACKING BIOMARKERS VIA A LAB RESULT EXPLAINER GUIDE OFFERS STANDARDIZED METRIC COMPARISONS. HOWEVER, THESE FINDINGS CANNOT ESTABLISH SUPERIORITY OVER RAVULIZUMAB BECAUSE THE MEDICINES HAVE NOT UNDERGONE A DIRECT HEAD-TO-HEAD COMPARISON.
THE DISTINCTION MATTERS BECAUSE BLOCKING C5 AND INHIBITING FACTOR B PRODUCE DIFFERENT BIOLOGICAL EFFECTS. C5 INHIBITION SUPPRESSES TERMINAL COMPLEMENT PATHWAY ACTIVITY, WHILE FACTOR B INHIBITION REDUCES ALTERNATIVE COMPLEMENT PATHWAY AMPLIFICATION. BOTH STRATEGIES MAY BENEFIT SELECTED PATIENTS MANAGED VIA AI TOOLS FOR ONCOLOGISTS AND NEPHROLOGY DECISION SUPPORT SYSTEMS, BUT THEIR RELATIVE EFFECTIVENESS REQUIRES DIRECT COMPARATIVE EVIDENCE.
CONCLUSION
THE FDA ACCELERATED APPROVAL MARKS AN IMPORTANT MILESTONE FOR ULTOMIRIS IN IgA NEPHROPATHY (IgAN). ITS PHASE III FINDINGS DEMONSTRATE SUBSTANTIAL PROTEINURIA REDUCTION, ADDING ANOTHER MECHANISM TO THE EVOLVING IgAN TREATMENT LANDSCAPE. GOVERNING COMPLIANCE WITH STANDARDS LIKE RULES FOR HEALTHCARE AI ENSURES RIGOROUS CLINICAL DEPLOYMENT ACROSS DIGITAL PLATFORMS.
HOWEVER, KIDNEY FUNCTION PRESERVATION REMAINS THE CENTRAL UNANSWERED QUESTION. THE ONGOING I CAN TRIAL MUST ESTABLISH WHETHER THESE EARLY IMPROVEMENTS TRANSLATE INTO SLOWER DISEASE PROGRESSION AND FEWER CASES OF KIDNEY FAILURE, DIALYSIS OR KIDNEY TRANSPLANTATION. PARALLEL BIOMARKER TRACKING VIA A LAB RESULT EXPLAINER GUIDE PROVIDES ESSENTIAL INSIGHTS, WHILE ADVANCED DECISION SUPPORT UTILITIES SUCH AS AI TOOLS FOR ONCOLOGISTS AND NEPHROLOGY PLATFORMS HELP FACILITATE COMPREHENSIVE PATIENT MONITORING.
FAQS ABOUT ASTRAZENECA’S ULTOMIRIS
COMPREHENSIVE ANSWERS REGARDING RAVULIZUMAB-CWVZ MECHANISMS, TRIALS, AND REGULATORY APPROVALS.
ULTOMIRIS (RAVULIZUMAB-CWVZ) IS A C5 COMPLEMENT INHIBITOR DEVELOPED BY ASTRAZENECA. IT BLOCKS TERMINAL COMPLEMENT ACTIVATION, REDUCING THE PRODUCTION OF INFLAMMATORY C5a AND C5b-9. THE FDA INDICATION COVERS PRIMARY IgA NEPHROPATHY IN ADULTS AT RISK OF DISEASE PROGRESSION. ADHERING TO PROTOCOLS SUCH AS RULES FOR HEALTHCARE AI ENSURES COMPLIANT CLINICAL DEPLOYMENT.
YES. THE FDA GRANTED ACCELERATED APPROVAL ON OCTOBER 21, 2026, TO REDUCE PROTEINURIA IN ELIGIBLE ADULTS. THIS APPROVAL USES PROTEINURIA AS A SURROGATE CLINICAL ENDPOINT. IN THE EU, THE EMA‘S CURRENT AUTHORIZED INDICATIONS DO NOT INCLUDE IgAN. US APPROVAL DOES NOT AUTOMATICALLY ESTABLISH UK OR EUROPEAN AUTHORIZATION.
THE I CAN TRIAL DEMONSTRATED A 46.6% REDUCTION IN PROTEINURIA FROM BASELINE AT WEEK 34, COMPARED WITH 5.6% FOR PLACEBO. THIS REPRESENTED A 43.4% PLACEBO-ADJUSTED REDUCTION. THE WEEK 34 INTERIM ANALYSIS ALSO SHOWED AN EARLY RESPONSE, WITH A 36.7% REDUCTION AT WEEK 10. EVALUATING DIAGNOSTIC LOGS VIA A LAB RESULT EXPLAINER GUIDE PROVIDES STANDARDIZED METRIC BENCHMARKS.
THE I CAN TRIAL IS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III CLINICAL TRIAL EVALUATING RAVULIZUMAB IN ADULTS WITH IgAN. RESEARCHERS RANDOMIZED 485 PARTICIPANTS TO RECEIVE TREATMENT OR PLACEBO. THE TRIAL ASSESSES PROTEINURIA AT WEEK 34 AND KIDNEY FUNCTION AT WEEK 106 eGFR ENDPOINT TO INVESTIGATE POTENTIAL LONG-TERM CLINICAL BENEFIT.
ULTOMIRIS IS ADMINISTERED THROUGH AN INTRAVENOUS INFUSION. FOR ELIGIBLE ADULTS WITH IgAN, TREATMENT BEGINS WITH A WEIGHT-BASED LOADING DOSE FOLLOWED BY MAINTENANCE DOSES EVERY EIGHT WEEKS. ITS LONG-ACTING COMPLEMENT INHIBITION ALLOWS LESS FREQUENT ADMINISTRATION THAN SOME OTHER COMPLEMENT-TARGETED TREATMENTS. ACTUAL DOSING MUST FOLLOW THE CURRENT PRESCRIBING INFORMATION.
COMMON ADVERSE REACTIONS IN THE IgAN TRIAL INCLUDED UPPER RESPIRATORY INFECTIONS, NASOPHARYNGITIS AND INFUSION-RELATED REACTIONS. HOWEVER, THE MOST IMPORTANT SAFETY CONCERN IS SERIOUS MENINGOCOCCAL INFECTION. THE FDA REQUIRES APPROPRIATE MENINGOCOCCAL VACCINATION AND ENROLLMENT IN THE RISK EVALUATION AND MITIGATION STRATEGY (REMS) PROGRAM. PATIENTS ALSO NEED PROMPT MEDICAL ASSESSMENT IF INFECTION SYMPTOMS DEVELOP.
THAT BENEFIT HAS NOT YET BEEN ESTABLISHED. ALTHOUGH ULTOMIRIS FOR IgA NEPHROPATHY REDUCES PROTEINURIA, RESEARCHERS STILL NEED TO DETERMINE WHETHER TREATMENT SLOWS KIDNEY FUNCTION DECLINE. THE WEEK 106 eGFR ENDPOINT WILL PROVIDE IMPORTANT EVIDENCE. UNTIL THEN, CLINICIANS CANNOT CLAIM THAT THE MEDICINE PREVENTS DIALYSIS OR KIDNEY FAILURE.
ULTOMIRIS BLOCKS C5 DOWNSTREAM, WHEREAS FACTOR B INHIBITORS SUCH AS IPTACOPAN INTERRUPT ALTERNATIVE COMPLEMENT PATHWAY ACTIVITY UPSTREAM. FACTOR B PARTICIPATES IN FORMING C3 CONVERTASE AND C5 CONVERTASE, WHICH AMPLIFY COMPLEMENT ACTIVATION. BOTH APPROACHES TARGET INFLAMMATION DIFFERENTLY, AND DIRECT COMPARATIVE TRIALS ARE NEEDED. SUPPORT SYSTEMS SUCH AS AI TOOLS FOR ONCOLOGISTS HELP FACILITATE ADVANCED MULTI-ARM CLINICAL DATA EVALUATIONS.
MEDICAL EDITORIAL NOTE
ULTOMIRIS ALSO HAS ESTABLISHED INDICATIONS FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS), GENERALISED MYASTHENIA GRAVIS (gMG) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD). ITS IgAN APPROVAL IS A SEPARATE INDICATION WITH ITS OWN CONFIRMATORY EVIDENCE REQUIREMENTS. GOVERNANCE COMPLIANCE WITH STANDARDS LIKE RULES FOR HEALTHCARE AI ENSURES MULTI-INDICATION SAFETY PROTOCOLS.
REFERENCES FOR FURTHER READING
- NEW ENGLAND JOURNAL OF MEDICINE – RAVULIZUMAB IN IgA NEPHROPATHY, PHASE III TRIAL.
- FDA – ULTOMIRIS FULL PRESCRIBING INFORMATION, OCTOBER 2026.
- KDIGO – 2025 IgA NEPHROPATHY CLINICAL PRACTICE GUIDELINE.
- EUROPEAN MEDICINES AGENCY – ULTOMIRIS EPAR.
- SANCTUARY – PHASE II RAVULIZUMAB CLINICAL TRIAL.
- ADDITIONAL CLINICAL BENCHMARKS SUPPORTED BY THE LAB RESULT EXPLAINER GUIDE AND EVALUATED VIA AI TOOLS FOR ONCOLOGISTS AND NEPHROLOGY PLATFORMS.
THIS ARTICLE IS FOR EDUCATIONAL PURPOSES AND DOES NOT REPLACE INDIVIDUALIZED MEDICAL ADVICE.
Dr. Kanza Sarfraz, M.B.B.S., is a medical doctor and graduate of Allama Iqbal Medical College, Lahore. She brings nearly seven years of clinical experience across tertiary-care hospitals, medical headquarters, and healthcare facilities in both the public and private sectors. Her clinical experience provides a practical perspective on healthcare delivery, emerging medical technologies, and the evolving role of artificial intelligence in medicine.